Go to content

Publications

484 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Organisation chart 2024

    This document gives an overview of the members of the Executive Board (RvB), the management of the National Health Care Institute ...

    Publication | 11-11-2024

  2. Taking care of good healthcare

    Video | 03-10-2024

  3. Advice - do not reimburse teclistamab (Tecvayli®) for the treatment of multiple myeloma

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse teclistamab ...

    Report | 10-07-2024

  4. Advice - reimburse dostarlimab (Jemperli®) for the treatment of endometrial cancer

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse dostarlimab ...

    Report | 10-07-2024

  5. Advice - reimburse sacituzumab govitecan (Trodelvy®) for the treatment of breast cancer (re-evaluation)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse sacituzumab govitecan ...

    Report | 09-07-2024

  6. Advice - reimburse naldemedine (Rizmoic®) for the treatment of constipation due to the use of strong analgesics (opioids)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse naldemedine (Rizmoic ...

    Report | 01-07-2024

  7. Advice - extending the reimbursement of axicabtagene ciloleucel (Yescarta®) for the treatment of lymphoma

    The National Health Care Institute has advised the Minister for Medical Care to extend the reimbursement of axicabtagene ...

    Report | 26-06-2024

  8. Advice - do not reimburse loncastuximab tesirine (Zynlonta®) for the treatment of lymphoma

    The National Health Care Institute has advised the Minister for Medical Care to not reimburse loncastuximab tesirine (Zynlonta®) ...

    Report | 12-06-2024

  9. Advice - do not reimburse glofitamab (Columvi®) for the treatment of lymphoma

    The National Health Care Institute has advised the Minister for Medical Care to not reimburse glofitamab (Columvi®) from the ...

    Report | 12-06-2024

  10. Advice - reimburse pegunigalsidase alfa (Elfabrio®) for the treatment of Fabry disease

    The National Health Care Institute has advised the Minister for Medical Care to reimburse pegunigalsidase alfa (Elfabrio®) from ...

    Report | 12-06-2024

Go to